Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ankyrin repeat domain 20 family member A11, pseudogene (ANKRD20A11P) is a human gene mapped to chromosome 21 and classified as a pseudogene, meaning it does not encode a functional protein. While it contains sequence elements characteristic of ankyrin repeat domains—motifs known to mediate protein–protein interactions—ANKRD20A11P lacks experimental evidence for biological function and is not considered a therapeutic target. Alternate names include C21orf81. There are no established disease associations, molecular functions, or pharmacological interactions. Pseudogene expression is sometimes used as a marker for transcriptional state, but there is no evidence for a direct biomarker or role in pathology specific to ANKRD20A11P[1][8][9][6][4][5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ankyrin repeat domain 20 family member A11, pseudogene (ANKRD20A11P).